Brief: Affimed Gets FDA's Fast Track Designation For Combination Therapy Of Afm24 With Atezolizumab For Egfr Wild-Type Non-Small Cell Lung Cancer
29/05/2024 11:46
May 29 (Reuters) - Affimed NV A28A.F :
* AFFIMED RECEIVES FAST TRACK DESIGNATION FOR COMBINATION
THERAPY
OF AFM24 WITH ATEZOLIZUMAB FOR EGFR WILD-TYPE NON-SMALL CELL
LUNG CANCER
Source text for Eikon: ID:nGNXbBNYyB
Further company coverage: A28A.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Affimed NV
See all newsBrief: Affimed Announces Receipt Of Nasdaq Delisting Notice
Brief: Affimed Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Brief: Affimed Reports Positive Clinical Update On Afm24/Atezolizumab Combination Therapy
Brief: Affimed NV Files For Common Stock Offering Of Up To $20 Million - SEC Filing
Brief: Affimed NV Files For Mixed Shelf Offering Of Up To $20 Million